Asian Journal of Biomedical and Pharmaceutical Sciences

Reach Us +1 (202) 780-3397

Short Communication - Asian Journal of Biomedical and Pharmaceutical Sciences (2024) Volume 14, Issue 107

Biotechnology in pharmacogenomics: Paving the way for personalized medicine

Koyel Sena *

Department of Pharmaceutical Sciences, University of Connecticut, USA

*Corresponding Author:
Koyel Sena
Department of Pharmaceutical Sciences, University of Connecticut, USA
E-mail: koyel@sen.edu

Received: 02-Sep-2024, Manuscript No. AABPS-24-151582; Editor assigned: 03-Sep-2024, PreQC No. AABPS-24-151582 (PQ); Reviewed: 16-Sep-2024, QC No. AABPS-24-151582; Revised: 20-Sep-2024, Manuscript No. AABPS-24-151582(R); Published: 27-Sep-2024, DOI: 10.35841/aabps-14.107.255

Citation: : Sena K. Biotechnology in pharmacogenomics: Paving the way for personalized medicine. Asian J Biomed Pharm Sci. 2024;14(107):255

Introduction  

Biotechnology and pharmacogenomics are transforming modern medicine by offering a tailored approach to healthcare. Pharmacogenomics, the study of how genes affect individual responses to drugs, allows for the development of personalized treatments that enhance drug efficacy and reduce side effects. This article explores how biotechnology is propelling pharmacogenomics forward, highlighting advancements, challenges, and the potential for a future where treatments are customized to each patient’s genetic makeup [1, 2].

Biotechnology serves as the backbone for pharmacogenomics, providing advanced tools and techniques that allow scientists to study genetic variations linked to drug responses. Through technologies like CRISPR gene editing and next-generation sequencing, researchers can now identify specific genetic markers associated with drug efficacy and safety. This understanding helps develop drugs that work more effectively with minimal adverse effects for patients with particular genetic profiles [3, 4].

Recent advances in biotechnology have accelerated pharmacogenomics research, making personalized medicine increasingly viable. Genomic sequencing enables the identification of genetic mutations or polymorphisms that influence drug metabolism and effectiveness. For example, in cancer treatment, pharmacogenomics is used to determine which chemotherapies will be most effective for patients based on their unique genetic profile, leading to better outcomes and fewer side effects [5, 6].

Pharmacogenomics has vast potential across various diseases, including cardiovascular diseases, mental health conditions, and infectious diseases. In cardiology, genetic testing helps doctors prescribe medications that are both safe and effective based on a patient's genetic predisposition. Similarly, in psychiatry, pharmacogenomics can prevent adverse drug reactions, especially for drugs that are processed differently in individuals due to variations in liver enzyme genes [7, 8].

Despite its promise, pharmacogenomics raises ethical and regulatory concerns. Issues such as genetic privacy, potential discrimination, and equitable access to personalized treatments are crucial considerations. Additionally, regulatory bodies face the challenge of establishing guidelines for genetic testing and ensuring that new, gene-tailored drugs meet safety and efficacy standards. Biotechnology firms and healthcare providers must navigate these challenges to create a fair and inclusive healthcare landscape. The future of pharmacogenomics looks promising, with potential for new biotechnological advancements to create more precise and accessible treatments. As genomic data grows, artificial intelligence may also play a role in interpreting this information and making predictions for drug development. The ongoing research and collaboration between biotechnological and pharmaceutical industries will be key to overcoming current challenges and bringing personalized medicine into everyday clinical practice [9, 10].

Conclusion  

Biotechnology’s contributions to pharmacogenomics are ushering in a new era of personalized medicine. With its ability to optimize drug efficacy and reduce adverse effects based on genetic factors, pharmacogenomics has the potential to revolutionize how we approach treatment for various conditions. As the field continues to evolve, addressing ethical and regulatory challenges will be crucial for realizing the full benefits of these advancements and ensuring a personalized healthcare future for all.

References

  1. McAndrew R, Helms Tillery SI Laboratory primates: their lives in and after research. 2016;3:502–508.
  2. Merigan WH. Chromatic and achromatic vision of macaques: role of the P pathway.. J Neurosci. 1989;9(3):776–783.

    3. Indexed at, Google Scholar, Cross Ref

  3. Mitchell AS, Thiele A, Petkov C, etal. Continued need for non-human primate neuroscience research: scientific discovery and clinical benefit.Curr Biol. 2018;28(20):R1186–R1187.

    4. Indexed at, Google Scholar, Cross Ref

  4. Baker SD, Li J, ten Tije AJ, et al. Relationship of systemic exposure to unbound docetaxel and neutropenia. Clin Pharmacol Ther. 2005;77(1):43–53.

    5. Indexed at,Google Scholar, Cross Ref

  5. Huizing MT, Giaccone G, Warmerdam LJ, et al. Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer.. The European Cancer Centre. J Clin Oncol. 1997;15(1):317–329.

    6. Indexed at, Google Scholar

  6. Rodriguez FJ, Lim KS, Bowers D, et al Pathological and molecular advances in pediatric low-grade astrocytoma.Annu Rev Pathol. 2013;8:361-79.

    7. Indexed at, Google Scholar, Cross Ref

  7. Huse JT, Holland E, DeAngelis LM. Glioblastoma: molecular analysis and clinical implications.. Annu Rev Med. 2013;64:59-70.

    8. Indexed at, Google Scholar

  8. Killela PJ, Reitman ZJ, Jiao Y, et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal.. Proc Natl Acad Sci US A. 2013;110:6021-26.

    9. Indexed at, Google Scholar

  9. Heaphy CM, de Wilde RF, Jiao Y, et al. Altered telomeres in tumors with ATRX and DAXX mutations . Science. 2011;333-42.

    10. Indexed at,Google Scholar

  10. Elsasser SJ, Allis CD, Lewis PW. Cancer New epigenetic drivers of cancers.. Science 2011;331:1145-46.

    11. Indexed at, Google Scholar, Cross Ref

Get the App